US equities |
META $622.64 ▼-1.26% TSLA $400.98 ▲+2.39% MU $914.39 ▲+1.18% NVDA $216.02 ▲+0.01% SPCX $148.27 ▲+0.93% AMD $547.55 ▲+3.06% INTC $92.19 ▲+1.90% SNDK $1,290.41 ▲+2.77%
FinancialContent

Acorda Therapeutics, Inc. - Common Stock (NQ:ACOR)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acorda Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Acorda Therapeutics Reports First Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
News headline image
3 Penny Stocks to Avoid as Interest Rates Rise in 2023 ↗
This article reveals the worst penny stocks to invest in for 2023, amid rising interest rates and a deteriorating macro environment. 
Via InvestorPlace
News headline image
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
From Acorda Therapeutics
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday! 
Via InvestorPlace
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which... 
Via FinancialNewsMedia
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Acorda Therapeutics
Via Business Wire
News headline image
ESTEVE Launches INBRIJA® in Spain
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda Therapeutics to Present at Sequire Biotechnology Conference
From Acorda Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
From Acorda Therapeutics
Via Business Wire
News headline image
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
From Acorda Therapeutics
Via Business Wire
News headline image
How Is The Market Feeling About Acorda Therapeutics? ↗
Acorda Therapeutics's (NASDAQ:ACOR) short percent of float has risen 230.3% since its last report. The company recently reported that it has 792 thousand shares sold short, which is 3.27% of all... 
Via Benzinga
News headline image
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
From Acorda Therapeutics
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million. 
Via Benzinga
News headline image
Acorda Therapeutics Reports Third Quarter 2022 Financial Results
From Acorda Therapeutics
Via Business Wire
News headline image
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >